Coherus Biosciences | CHRS - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 58.94B 4.03B 2025-12
Acadia Pharmaceuticals USD 0 0 2025-03
Akebia Therapeutics USD 36.39M 11.85M 2026-03
ALKERMES USD 1.48B 1.2B 2026-03
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Amgen USD 51.89B 1.88B 2026-03
Baxter International USD 8.62B 852M 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Fujifilm JPY 642.24B 70.37B 2025-12
Gilead Sciences USD 20.86B 1.27B 2026-03
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
Merck USD 46.67B 77M 2026-03
Myriad Genetics USD 120.3M 400K 2026-03
Pacira USD 367.66M 4.53M 2026-03
Perrigo USD 3.62B 17.5M 2026-03
Pfizer USD 60.57B 1.08B 2026-03
PTC Therapeutics USD 286.94M 1.74B 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Teva Pharmaceutical Industries USD 14.02B 971M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12
Xencor USD 82.12M 5.64M 2026-03
Zoetis USD 9.04B 3M 2026-03